Aim: Tacrolimus is a substrate of CYP3A4 and CYP3A5. The present study investigated the
impact of the CYP3A4* 1/* 1G polymorphism compared with CYP3A5 genotypes on the …

Background Genetic polymorphism is an important factor that influences tacrolimus
concentrations and has the potential to predict the optimal dosage of tacrolimus in …

In the present study, we performed a systematic review and meta-analysis on published data
to examine the impact of CYP3A5 6986A> G and ABCB1 3435C> T polymorphisms on …

Purpose: Calcineurin inhibitors (CNIs) such as tacrolimus are a major immunosuppressive
therapy after renal transplantation, which inhibit cytokine expression. The pharmacokinetics …

The aims of this study were to investigate the influence of CYP3A5 and MDR1 genetic
polymorphisms on tacrolimus pharmacokinetics in Chinese renal transplant recipients, so as …

Purpose To explore the relationship between rs2291075 polymorphism in SLCO1B1 gene,
which encodes an influx transmembrane protein transporter, and tacrolimus dose–corrected …

Introduction: This study aimed to evaluate the effects of single nucleotide POLYMORPHISM
s CYP3A 4* 1B and CYP3A 5* 3 on TACROLIMUS dose requirement among kidney …

Purpose The once daily formulation of tacrolimus is an important immunosuppressive drug.
Interpatient variability in metabolism has been related to genetic variation in CYP3A4 and …

BACKGROUND: Genetic polymorphisms of metabolism enzymes or intestinal drug
transporters may affect pharmacokinetic responses to immunosuppressive drugs in renal …

Background We investigated a long-term association between donor/recipient CYP3A5
polymorphisms, pharmacokinetics of tacrolimus, and recipient outcomes in settings of living …